Posted by Michael Wonder on 13 Aug 2025
Creative Medical Technology secures FDA fast track designation for CELZ-201-DDT - advancing breakthrough therapy for chronic lower back pain
13 August 2025 - Creative Medical Technology Holdings today announced that the US FDA has granted fast track designation to its lead investigational therapy, CELZ-201-DDT, for the treatment of degenerative disc disease, a major cause of chronic lower back pain and disability.
CELZ-201-DDT, part of the Company’s proprietary AlloStem platform, is an allogeneic perinatal cell therapy administered via minimally invasive, ultrasound-guided intramuscular injections.
